Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-limiting toxicity (DLT), toxicity profile,
maximum tolerated dose (MTD) and characterize the pharmacokinetics of biweekly PEP02
treatment.